References
- K.N.SaxenaC.K.DuaMalignant hyperthermia – a case reportIndian J Anaesth512007534535
- J.PunjS.BhatnagarA.saxenaMalignant hyperthermia in the Indian subcontinent: non-availability of dantrolene – a cause for concern?Internet J Pharmacol11200110.5580/1a7
- C.V.GopalakrishnanB.SuparnaV.ArunA rare case of malignant hyperthermia in the Indian subcontinentAnaesthesia65201011421152
- G.JainS.K.GuptaS.TharwaniD.K.SinghRare case of hyperthermia in aluminum phosphide poisoningIndian J Forensic Med Toxicol420102627
- Gupta D.RamakantP.K.SinghPostoperative hyperpyrexia: retracing malignant hyperthermiaJ Anaesthesiol Clin Pharmacol282012405406
- AlokSharmaHemangiKarnikSanjayKukrejaKanchanJaggerIndian J Anaesth5622012 Mar-Apr21221310.4103/0019-5049.96327
- M.G.LarachA.R.LocalioG.C.AllenA clinical grading scale to predict malignant hyperthermia susceptibilityAnaesthesiology801994771779
- P.M.HopkinsMalignant hyperthermia: advances in clinical management and diagnosisBr J Anaesth8512000118128
- European Malignant Hyperpyrexia GroupA protocol for the investigation of malignant hyperpyrexia (MH) susceptibilityBr J Anaesth56198412671269
- P.K.GuptaP.M.HopkinsMalignant hyperthermia in IndiaAnaesthesia6520101063106510.1111/j.1365-2044.2010.06532.x
- M.G.LarachNorth American Malignant Hyperthermia GroupStandardization of the caffeine halothane muscle contracture testAnesth Analg691989511515
- K.P.E.Glahn1F.R.EllisP.J.HalsallC.R.MüllerM.M.J.SnoeckA.UrwylerRecognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia GroupBr J Anaesth1054201041742010.1093/bja/aeq243
- D.CarpenterR.L.RobinsonR.J.QuinnellGenetic variation in RYR1 and malignant hyperthermia phenotypesBr J Anaesth1032009538548
- R.L.RobinsonP.M.HopkinsA.CarsanaSeveral interacting genes influence the malignant hyperthermia phenotypeHum Genet1122003217218
- Keith G.AllmanIain H.WilsonAdrian O’ Donnell drug formulary in Oxford handbook of anaesthesia2ond ed.2006Oxford University PressNew Yorkp.1118